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INTRODUCTION
          Human immunodeficiency virus type1 is a primary cause 
of AIDS, which is a slow and degenerative disease of human 
immune  system.  The  pathogenesis  of  HIV-1  is  complex  and 
characterized by interplay of both host and viral  factors. Most 
researchers believe that  HIV originated in sub-Saharan Africa 
during 20th century1 and is now a pandemic, with an estimated 
33.2 million people now living with the disease worldwide. As of 
January  2006,  the   United  Nations  Programme on  HIV/AIDS 
(UNAIDS) and World Health Organization (WHO) estimated that 
AIDS has killed more than 25 million people since it  was first 
recognized  on  June  5,  19812,  making  it  one  of  the  most 
destructive epidemics in recorded history2.  
 2.1 HIV-1
        HIV-1 is a lentivirus belonging to the retrovirus family. The 
virus is diploid and contains two plus-stranded RNA copies of its 
genome. The approximately 9 kb RNA genome encodes at least 
9 proteins, Gag, Pol, Env, Tat, Rev, Nef, Vif, Vpu and Vpr3
         Three major classes of HIV-1 have emerged: M (main), N 
(new), and O (outlier)4. Among M group viruses, which account 
for  >90% of  HIV  infections  worldwide,  there  are  9  subtypes, 
called clades, designated by the letters A-D, F-H, J, and K, as 
well as many recombinant forms.
2.2 HIV and genetic variation5       
Virus type Sub type Predominant area
HIV-1 M A Africa, Eastern Europe
B Europe,North 
America,Austrilia,Thaila
nd
C Southern Africa, India
D East and Central Africa
E Thailand
O\N West Africa
2.3 Pathogenesis
        Infection is transmitted when the virus enters the blood or 
tissues of a person and comes into contact with a suitable host 
cell  principally  CD4  lymphocyte.  B  lymphocyte,  monocytes, 
macrophages,  including  specialized  macrophages  such  as 
alveolar  macrophage  in  lungs  and  Langerhans  cells  in  the 
dermis, glial cells and microglia in the CNS are also susceptible. 
The  infection  spreads  to  the  lymphatic  tissue  that  contains 
follicular dentritic cells that may act as storage place for latent 
viruses.  Over  time,  virus  replication  leads  to  the  immune 
system6. 
Fig:1 
HIV transmission and the establishment of HIV reservoirs. (A) 
Interactions of HIV envelope glycoprotein, CD4, and CCR5 or 
CXCR4 co receptors Trigger fusion and entry of HIV. (B) Outline 
of  the  sequence  and  time  course  of  events  involved  in  viral 
dissemination. 
2.4 Immunology
Individuals  infected  with  HIV  show  both  cellular  and 
humoral  (antibody)  immune responses to the virus,  but  these 
responses  are  unable  to  prevent  the  ultimate  progression  of 
disease  in  the  great  majority  of  infected  individuals.  Cellular 
responses  are  mediated  by  CTLs  (CD8  cells)  and  helper  T 
lymphocytes (CD4 cells) 8. 
Fig:2 Viral Pathogenesis and immune response9
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2.5 HIV Replication cycle10, 11, 12
Fig:3
Summary of HIV life cycle
1.  Free  virus  enters  into  blood  stream of  human  via  various 
transmissions, and then recognizes 
    the site of infection and binds to it.
2. Fused with cell membrane and penetrate to cytoplasm
3.  Internalization  and  uncoating  supported  by  various  host 
factors
4. Single standard viral RNA transcribed into double standard 
DNA by reverse transcriptase
5.  Integrate  their  double  standard  DNA  into  host  genome 
influenced by IN and VPR
6. Proviral formation
7. Proviral transcription by TAT 
8.  RNA  of  virus  processed  by  REV  and  transported  into 
cytoplasm
9. Formation of unspliced product of genomic RNA influenced by 
ENV.
10. Viral translation
11. Viral membrane protein transported to cell membrane
12. Assembling of viral proteins in immature virus
13. Virion release through budding process influenced by NEF
14. Maturation of virus by protease enzyme
Each step in replication cycle is equally important to make 
an infective virion and thus each step acts as novel target for 
antiviral  strategies  .Focusing  the  molecular  strategies  which 
delays  the  progression  or  block  replication  of  HIV-1  infected 
individual’s gains paramount importance.
Table:1    Molecular  strategies  against  targets  in  HIV 
replication cycle3, 11, 13, 14, 15
Targets
Strategy  against 
target
Drugs
1 1.  chemokine  ligand 
mediates  receptor 
blokade
RANTES
1.AOP
2.PSC
2.Antisence RNA VRX4-96
3.Ribozymes -
4.SiRNA(0.5  Kb 
dsRNA  CD4  domain 
of SU)
-
5.Chimeric  \fusion 
protein
PRO 542
6.Intracellular 
antibody (sFUS)
Cynovirin-11KDa 
protein  isolated  from 
cyano bacteria
7.Monoclonal 
antibody
Mab 12G5
Anti ECL 2
TNX-355
2
A.Receptor blocking
1.chemicals
2.Mab
B.GP 120 inhibition
AMD 3100
AK 602
AMD 070
INCB 9471
Maraviroc *
Enfuvirtide *
PRO 140
HGS 0004
BMS 378806
4 1.NRTI Lamivudine *
Abacavir *
Zidovudine *
Stavudine *
Didanosine *
Emtricitabine *
Tenofovir *
Apricitabine 
Amdoxovir 
Dioxolan 
ethyminedine
Elvucitabine
KPUI 461
MIV 210
RAcivir
2.NNRTI Delavirdine *
Efavirenz *
Nevirapine *
(+)calanolide
BILR 355 B
Etravirine
MIV 150
Rilpivirine
3.Ribozymes -
4.RNA decoy tRNA 3 Lys mutant
5.Anti RT dimerization Small peptide
15-19 AA
6.RNA aptamer -
7.Anti sense -
5
1.Irreversible 
noncompetitive 
enzyme inhibition
Dicaffeoyl quinic acids
2.other chemicals 2,4  dioxo  butanoic 
acid analog
Reltegravir
GSK 364735
Elvitegravir
3.Dinudotide Pdc pISodv
4.sFU -
5.SiRNA -
7.
1.Antisense RNA HGTV43
2.RNA decoys TAR decoys
3.Si RNA Tat  SiRNA Vs NF bp 
65
4.Transdominant 
negative protein
Tat mutant
5.Ribozymes RR Z2
6.Fusion protein -
7.Mab BI-201
8.chemical agent
Benzodiazepine  oligo 
pyrrole hybrids
Aromatic  polyamide 
carrying halogen
1.TAPB-Br
2.TAPP-Br
8. 1.TNP Rev M10
Rev 38
Sam 68 mutant
2.RNA decoys
PRE decoys
C41 nucleotide
Rre sciIAB
RNA decoy
3.SFU NES specific SFU
4.Antisense Synthetic 
phosphorothiosate 
oligodeoxy nucleotide
5.RNA aptamer -
6.Antibiotic
Leptomycin B
NUP 214\CAN
Delte-CAN
7.Fusion protein NSIRM –Rev mutant
8.intercalating dye Pyronin Y
Diphenyl furan
9. 1.Antisense Anti  sense  to  U3   5' 
LTR gag –Env
Env region
2.Gag TNPS -
3.sFU SFU 105
4.Anti  intracellur 
protein 
Poly arginine peptide
12.
1.Anti sense RNA  1.43kb  to  psi-
gag region
2.Ribozymes -
3.RNA decoys -
13
1.Nef TNPs -
2.Anti sense -
3.Ribozymes -
14. 1.Gag TNP -
2.Anti sense -
3.Protease inhibitor Saquinavir *
Indinavir *
Ritonavir *
Nelfinavir *
Amprenavir *
Lopinavir *
Atazanavir *
Lopinavir *
Atazanavir *
Daruanvir *
Tipnavir *
Darunavir *
Fosampnonavir *
PPL-100
4.Maturation inhibitor Bevirrimat *
2.6 Natural progression of HIV-1
         Natural history of infection encompasses an acute phase 
that lasts months, followed by an early /clinically latent phase 
that typically 3-10 years, and ultimately by the immune collapse 
characterized by AIDS7.
Fig:4
Four stages of HIV infection can be described9
i) Primary infection: Infection with HIV results in rapid proliferation of the 
virus in blood and lymph nodes.  The infected person may experience a 
seroconversion illness, which usually resolves within weeks.  The CD4 
cell  count  declines  rapidly  before  virus  is  controlled  by  the immune 
system, whereupon the count returns to near normal.
ii) Early immune deficiency (CD4 cell count>500/ML):During this phase 
the immune system has controlled the virus, which is largely restricted 
to lymphoid  tissue.    In  this  phase,  damage inflicted by the virus is 
limited to the regenerative capacity of the immune system and people 
with HIV are usually without symptoms.
iii) Intermediate immune deficiency (CD4 cell count 200-500/ML): Viral 
replication is very high and CD4 cell turnover is rapid.  Subtle signs and 
symptoms indicating compromise of immune system begin to appear.
iv) Advance Immune Deficiency (CD4 cell  count <200/ML): The virus which 
proliferates  throughout  the  body  overcomes  the  immune  system.   Major 
opportunistic infections and malignancies become increasingly common and 
require increasing medical intervention
Table:2 Natural History of HIV Infection in adult
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2.7 Classification of HIV Disease
HIV  damages  the  immune  system,  leaving  the  infected 
person vulnerable to a variety of infections (called "opportunistic" 
infections to indicate that  they arise in  the setting of  immune 
impairment).  The  effect  of  HIV  on  the  immune  system  is 
monitored by measuring the CD4 (helper) lymphocyte count in 
the blood. A normal CD4 count (between approximately 600 and 
1,200  cells/µL)  indicates  that  the  immune  system  has  not 
undergone  sufficient  damage  to  put  the  individual  at  risk  for 
opportunistic illness
1993  Revised  Classification  System  for  HIV  Infection  and 
Expanded  Surveillance  Case  Definition  for  AIDS  Among 
Adolescents and Adults by CDC
CD4+ T-Lymphocyte Categories
The three CD4+ T-lymphocyte categories are defined as follows:
Category 1: greater than or equal to 500 cells/mL
Category 2: 200-499 cells/uL
Category 3: less than 200 cells/uL
Clinical Categories
The clinical categories of HIV infection are defined as follows:
Category A
Asymptomatic HIV infection
Persistent generalized lymphadenopathy
Acute  (primary)  HIV  infection  with  accompanying  illness  or 
history of acute HIV infection 
Category B
Bacillary angiomatosis
Candidiasis, oropharyngeal (thrush)
Candidiasis,  vulvovaginal;  persistent,  frequent,  or  poorly 
responsive to therapy
Cervical  dysplasia  (moderate  or  severe)/cervical  carcinoma in 
situ
Constitutional  symptoms,  such  as  fever  (38.5  C)  or  diarrhea 
lasting greater than 1 month
Hairy leukoplakia, oral
Herpes zoster (shingles), involving at least two distinct episodes 
or more than one dermatome
Idiopathic thrombocytopenic purpura
Listeriosis
Pelvic inflammatory disease, particularly if complicated by tubo-
ovarian abscess
Peripheral neuropathy
Category C
Candidiasis of bronchi, trachea, or lungs
Candidiasis, esophageal
Cervical cancer, invasive *
Coccidioidomycosis, disseminated or extrapulmonary
Cryptococcosis, extra pulmonary
Cryptosporidiosis,  chronic  intestinal  (greater  than  1  month's 
duration)
Cytomegalovirus disease (other than liver, spleen, or nodes)
Cytomegalovirus retinitis (with loss of vision)
Encephalopathy, HIV-related
Herpes  simplex:  chronic  ulcer(s)  (greater  than  1  month's 
duration); or bronchitis, pneumonitis, or esophagitis
Histoplasmosis, disseminated or extra pulmonary
Isosporiasis, chronic intestinal (greater than 1 month's duration)
Kaposi's sarcoma
Lymphoma, Burkitt's (or equivalent term)
Lymphoma, immunoblastic (or equivalent term)
Lymphoma, primary, of brain
Mycobacterium avium complex or M. kansasii, disseminated or 
extra pulmonary
Mycobacterium  tuberculosis,  any  site  (pulmonary  *  or  extra 
pulmonary)
Mycobacterium,  other  species  or  unidentified  species, 
disseminated or extra pulmonary
Pneumocystis carinii pneumonia
Pneumonia, recurrent *
Progressive multifocal leukoencephalopathy
Salmonella septicemia, recurrent
Toxoplasmosis of brain
Wasting syndrome due to HIV
The World Health Organization has developed a clinical 
staging system for HIV infection. This system relies more heavily 
on clinical rather than laboratory evaluation, and has been used 
widely in resource-constrained areas where laboratory testing is 
not widely available.
WHO  STAGING  SYSTEM  FOR  HIV  INFECTION  AND 
DISEASE IN    ADULTS AND ADOLESCENTS
Clinical Stage I:
Asymptomatic
Persistent generalized lymphadenopathy (PGL)
Performance scale 1: Asymptomatic, normal activity
Clinical Stage II:
Weight loss, < 10% of body weight
Minor  mucocutaneous  manifestations  (seborrheic  dermatitis, 
prurigo, fungal nail
infections, recurrent oral ulcerations, angular cheilitis)
Herpes Zoster, within the last 5 years
Recurrent  upper  respiratory  tract  infections  (i.e.,  bacterial 
sinusitis) and/or
Performance scale 2: symptomatic, normal activity
Clinical Stage III:
Weight loss, > 10% of body weight
Unexplained chronic diarrhoea, > 1 month
Unexplained  prolonged  fever  (intermittent  or  constant),  >  1 
month
Oral candidiasis (thrush)
Oral hairy leukoplakia.
Pulmonary tuberculosis, within the past year
Severe bacterial infections (i.e., pneumonia, pyomyositis) and/or 
performance scale
3: bed-ridden, < 50% of the day during the last month
Clinical Stage IV:
HIV wasting syndrome, as defined by CDC
Pneumocystis carinii pneumonia
Toxoplasmosis of the brain
Cryptosporidiosis with diarrhoea, > 1 month
Cryptococcosis, extrapulmonary
Cytomegalovirus  (CMV) disease of  an organ other  than liver, 
spleen or lymph nodes
Herpes  simplex  virus  (HSV)  infection,  mucocutaneous  >  1 
month, or visceral any
du ration
Progressive multifocal leukoencephalopathy (PML)
Any  disseminated  endemic  mycosis  (i.e.  histoplasmosis, 
coccidioidomycosis)
Candidiasis of the oesophagus, trachea, bronchi or lungs
Atypical mycobacteriosis, disseminated
Non-typhoid Salmonella septicaemia
Extrapulmonary tuberculosis
Lymphoma
Kaposi’s sarcoma (KS)
HIV encephalopathy, as defined by CDC
And/or  Performance  scale  4:  bed-ridden,  >  50%  of  the  day 
during the last month
(Note:  both  definitive  and  presumptive  diagnoses  are 
acceptable.)
2.8 Epidemiology
There  are  currently  approximately  33.2  million  persons 
living with HIV\AIDS. Among them adult prevalence is 0.8%. As 
per 2007 WHO report, adult and children deaths due to AIDS 
are 2.1% million, and adult and children newly infected with HIV 
is 2.5 million.
In  India,  the  adult  prevalence  %  is  0.36;  total  prevalence  is 
0.9%.Total population of HIV in India is 2.5 million at 2007 
Adult prevalence % in different states of India is19,
                                                    Table:3
State Prevalence %
Andrapradesh, 
Nagaland, 
Manipur
1-2%
Karnataka, 
Maharashtra, 
West  Bengal, 
Mizoram
0.5-1%
Tamil Nadu 0.2-0.5%
Rest 0-0.2%
                        
Fig:5   HIV population of India in millions
India accounts for 10% of global HIV burden and 65% of that in 
South and
South East Asia.
2.9 Treatment
Currently,  all  FDA-approved  antiretroviral  medications  work  by 
inhibiting 1 of 3 steps in the life cycle of HIV:
1. Blocking the reverse transcriptase (RT) enzyme. The RT enzyme 
is used by the virus to convert its RNA into DNA after the virus 
enters the cell  but before it enters the nucleus. All nucleoside 
and  nucleotide  analogues  as  well  as  NNRTIs  function  by 
interfering with the activity of this enzyme.
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2. Blocking the protease enzyme. Protease inhibitors, as their name 
indicates,  inhibit  the  action  of  the  HIV  protease,  namely, 
cleaving protein products of the viral structural genes into the 
functional subunits needed to create new infectious virions.
3. Inhibiting fusion of the viral and host membranes. By attaching 
itself to the HIV envelope glycoprotein gp41, fusion inhibitors 
prevent formation of the "hairpin" structure required for fusion 
of the HIV and host cell membranes, and thus prevent viral entry 
into the host cell.
These drugs are classified as21,
a – NRTI, b - NNRTI, c – PI, d – FI
2.9.1 Selection of ART
Combination of these drugs are possible, termed as HAART, it 
could  exert  more  effectiveness.  Selection  of  ART  regimens  for 
programmes  and  individual  patients  should  consider;  potency, 
frequency  of  dosage,  side  effects,  maintance  of  future  treatment 
options,  the  anticipated  adherence  of  the  patient  population  to  a 
regimen, need for storage, concurrent conditions, the potential for 
resistant viral strains and cost access.
2.9.1.1 Possible HAART combinations
Table:4
No of possibilities Choice  of 
combinations
1 A
2 2a+b
3 2a+c
4 3a
5 2a+2b
6 A+b+c
7 B+c
8 A+b+c+d
9 c\r alone
10 4a
11 3a+b
Among these,
Current recommendation 2, 3, 4
Not  possible  category 
(already  trailed)  but  some 
cases recommends e.g. failure 
in 2a+c
5, 6,and 11
Under investigation 7, 8 9, 10
2.9.1.2 Current recommended HAART regimens
Clinicians are recommended to construct a regimen by choosing one 
component from Column A + one component from Column B.
Table:5
2.9.2 Initiation of HAART22, 23
Optimal timing of ART initiation for persons with HIV infection is of 
great clinical and public health importance. There is strong evidence 
supporting the use of the CD4 T cell count as the major determinant in 
initiating therapy. The plasma HIV RNA level remains an independent 
predictor of clinical outcome in patients who do not receive ART and 
is the best available guide for monitoring the effectiveness of ART.
2.9.2.1 Current guidelines24,25, 26
Current  guidelines  from the  international  AIDS  society-USA (IAS-
USA),  DHHS,  BHIVA  all  recommends  ART  for  individuals  with 
symptomatic  HIV infection.  These  established  guidelines  uniformly 
recommend initiating ART before the CD4 count is < 200 cells\mm3.
WHO  recommends  that  in  ART  programmes  in  resource-limited 
settings HIV infected  adolescent  and adults  should start  ART when 
they have clinical AIDS, regardless of CD4 count, When TLC can be 
assessed, in addition people with WHO stage 2 or stage 3 HIV diseases 
should be offered treatment when CD4 counts are available, all HIV 
infected people with less than 200 CD4 cells\mm3 should be offered 
treatment.
2.9.3 Acute HIV treatment27
Most individuals with acute HIV infection are symptomatic and 
could be targeted for early therapy. Information on long-term outcomes 
of treatment  for  acute  HIV infection is  limited.  Possible  benefits  of 
early therapy include: less severe acute disease, lower initial viral "set 
point"  with  potential  slower  disease  progression,  preservation  of 
immune function, and possible reduction in viral transmission. On the 
other hand, potential risks include drug toxicities and, if virus is not 
fully suppressed, drug resistance that limits further treatment options. 
Based on limited available data, some researches found that, treating 
HIV  during  the  acute  HIV  infection  stage  may  boost  the  immune 
system and slow the progression of HIV disease.
One study followed HIV positive persons who started HAART 
in the acute infection stage. This person had significantly better viral 
load and CD4 counts,  compared to HIV positive person who began 
HAART at a later stage.
2.9.4 Survival benefits of HAART30, 31
The  time  from  first  diagnosis  of  AIDS  to  death  has  been 
characterized separately from the incubation time from infection 
to AIDS as AIDS survival time. Improved median survival of 
AIDS  patients  was  observed  on  HAART.  In  the  Multicenter 
AIDS  Cohort  Study,  the  estimated  median  time  from 
seroconversion  to  death  for  a  person  infected  at  age  30  was 
associated with use of combined therapy and increased nearly 2 
years. 
In  another  one  study,  found  that  median  survival  time 
increased from 19 to 30 months among all AIDS patients over 
age 35 years with a CD4 lymphocyte count less than 100 cells/µl 
and receiving antiretroviral therapy.
2.10 Laboratory monitoring of HIV
HIV infection is spreading rapidly in India.  The infection can 
only be detected by laboratory tests, as there is a long asymptomatic 
period when the individual is infectious and can spread disease but has 
no specific symptoms or signs of disease.  The role of the laboratory is 
very important and it is essential that the highest standards are not only 
maintained in each laboratory but are also regularly monitored.
Laboratory  surrogate  markers  of  HIV infection  are  needed to 
provide information about the stages and course of disease, especially 
in the years prior to the development of clinical signs and symptoms of 
immune disorder, e.g. OP infections or neoplasia. Changes in immune 
parameters also reflect damage to the host caused by HIV infection and 
indicate pathogenic mechanisms of disease.
2.10.1  Classification  of  surrogate  markers  based  on  disease 
pathogenesis
In clinical context “surrogate” implies some responsibility e.g. 
an ability to contribute substantial information about clinical prognosis. 
A  separate  system  for  classifying  the  stages  of  surrogate  marker 
evaluation has been proposed by Mildvan et al ,this involves progress 
in staging from detecting of HIV infection, to relation to prognosis and 
finally to relevance to therapeutic benefit.
Table:6
I. VIRAL FEATURES
P24  AG ASSAY
HIV-1  RNA  LEVEL 
BY  PCR,  BDNA, 
NABA
II  immunological 
features
Cd7 lymphocyte count
CD4:CD8
CD4%
IL-2R
TNF-α
INF-γ
IL-4
MHC-1R
III  Immune  system 
activation
Ig G
Ig A elavation
CD38 expression
But  the  cost  of  monitoring  is  prohibitively  high.  As  antiretroviral 
therapy  is  becoming  more  affordable  and  accessible,  inexpensive 
laboratory tests are also needed to monitor the progression of disease in 
HIV infected individuals, living in resource-limited environments most 
heavily impacted by the epidemic. Low cost predictors include serum 
albumin,  BMI,  TLC,  DTH  reaction,  ALT,  AST  measurements  and 
HGB measurement.
2.10.2  Parameters  measured  in  HIV  progression  and  their 
significance32, 33, 34, 35
Table:7
Parameters  Normal 
condition
        HIV-AIDS      Other disease
1.CD4  count  in 
cells\mm3
CD4 marker is 
exclusively 
specific 
marker  in  T-
cells  for  HIV 
particle
Immunological 
detoriation
-
2.CD4:CD8 "
3.CD4% "
4.VL  in 
copies\pl(positiv
e)
- HIV-factors -
5.  P24Ag 
(positive)
Measures  the 
viral  capsid 
(core)  P24 
protein, 
directly 
reflects  the 
amount  of 
antigen 
persist  in  our 
body.
6.  C-reactive 
protein 
(negative)
Reflects 
activation/ 
production  of 
IL-4
Immunological 
alteration
Atherosclerosis, 
cancer,  end  stage 
renal disease
7.β2Microglobuli
n  in 
mg\dl(positive)
Reflects 
activation  of 
MHC I K
Cancer,  renal 
impairment,  all 
immuno  deficiency 
status
8.S  neopterin  in 
ng\ml(positive)
Reflects more 
production  of 
IFN -γ
TB,  Kindney  graft 
rejection,  viral, 
fungal,  bacterial 
infections,  aseptic 
meningoencephalit
is,  collegen 
vascular  disease, 
malignancies
9.s  IL  -2R  in 
(positive) u/ml
Reflects more 
production  of 
IL-2
Cancer
10.  S-TNFα2RI 
in ng/ml(positive)
Reflects 
moreproducti
on of TNF-α
Cancer
11.  S-albumin 
%g/l(negative)
Decrease 
their  level 
where 
Severe  liver 
dysfunction  on 
ARC  cocci 
So  many  hepatic 
impaired condition
impaired  liver 
function
dioidomycosis 
hepatitis-  co-
infection12.  ALT,AST 
(negative)
Reflects  liver 
function
13.Hb(negative)
Reflects 
anemic 
condition
Bone  marrow 
depression, 
severe  anemic 
condition
Neutropenia, 
malnutrition, 
malabsorption, 
myelodysplasia
Cytomegaloviral 
infection, 
mycobacterium 
avium  complex, 
crytocococcus,
Histoplasmosis, 
drug  induced 
toxicity  and  HIV 
factor,
Malaria,  folate 
deficiency,  iron 
deficiency,  hook 
worm  infection,  α 
thalassaemia, TB
14.  Platelet 
count(negative)
Reflects 
thromobolytic 
function
Thrombocytopen
ia purpurae
Common  for 
physical 
destruction
15.  Haemotocrit Reflects  total Hematological 
(negative) red blood cell 
volume  and 
their status
complication
16. 
TLC(negative)
Reflects 
lymphocyte% 
multiplied with 
WBC 
leucopenia,
lymphopenia
17. BMI (low)
Reflects 
alteration  in 
growth factor
Severe  weight 
loss (>10%)
TB,  Typhoid, 
cholera(chronic) 
and other amoebic 
conditions
2.11   Impact of anemia in HIV progression36,37
Clinical assessment prior to the initiation of ART includes 
documentation of past medical history,  identification of current 
and  past  HIV  related  illness,  identification  of  co  morbidities, 
medications in  use and current  symptoms and signs.  Clinical 
course,  co  morbidity  and  pattern  of  OI  vary  from  patient  to 
patient and from country to country. But anemic co morbidity is 
common to all.
Anemia  is  frequently  experienced  by  HIV  positive 
individuals  especially  women.  Prevalence  of  anemia  in 
asymptomatic period is 30%, and in clinical AIDS is 80-90%. HIV 
related  anemia  can  involve  multiple  casual  mechanisms,  and 
often several of these are operative in the same patient at the 
same time. These causal mechanisms include HIV itself, which 
can  induce  chronic  inflammation,  and  slow  red  blood  cell 
production.  In  addition,  drug  toxicities,  OI,  malabsorption, 
syndromes  leading  to  folate  or  vitamin  B12  deficiency,  blood 
loss,  iron  deficiency,  lymphoma  and  other  AIDS-related 
malignancies can all cause or contribute to anemia
Fig:6
  
Anemia has been associated with decreased quality of life 
and  decreased  survival,  has  been  shown  to  be  a  strong 
independent predictor of disease progression and death. Even 
modest (1g\dL) changes in HGB may associate with a significant 
increased risk of death. 
         After HAART was introduced, the prevalence of anemia in 
HIV infection declined. With increased use of HAART, we have 
witnessed a decline in OI with malignance and infection-related 
malabsorption  syndrome.  Also,  HAART  may  reduce  levels  of 
HIV  chronic  inflammation.  All  of  these  factors  can  improve 
anemia,  and  are  most  likely  responsible  for  the  decrease  in 
cases of severe anemia noted during the HAART era. Recovery 
from  anemia  is  associated  with  improved  survival  and  that 
treatment  of  mild-moderate  anemia  in  HIV patients  enhances 
functional  ability  as  well  as  improves  quality  of  life,  is  of 
important  to  both  patients  and  treating  physicians.  Taken 
together, this information underscores the continuing importance 
of monitoring for anemia and maintaining normal HGB levels as 
a treatment goal, even as ART continue to improve.
OBJECTIVE OF STUDY
1. To integrate the different ways of HIV classification and to 
develop a classification model which will be more relevant 
for resource limited settings.
2. To study the interrelationship between the cheaply available 
markers, (Hb & TLC) with CD4 and to develop a model for 
“CD4 decline in HIV” for therapeutic decision making.
         3.  To  derive  an  algorithm  based  on  HGB  and  TLC 
measurement for 
            guide to initiation Of ART
 4. To review the molecular strategies against target in HIV 
replication cycle
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3. MATERIALS AND METHODS
3.1 Instruments Required
    (1) Sysmex Kx-21                                       –   Automatic Blood 
Content
                                                                             Analyzer.
          (2)Flow Cytometer- Becton Dickinson       _   CD4 Counter
3.2. Protocol for Complete blood Count 
a)Sample: 
HIV patients Blood (iv source)
b)Diluation: 
20µl  blood  diluted  with  300µl  cell  pack  which  contains, 
HGB/WBC lyse reagent –   Stromolyser, cell clean- detergent and 
diluent by machine itself.
c)Detection:
HGB  Detected  by  photo  electric  method  using  540nm 
Principle behind it is Cyanomethaemoglobin method.
d)Determination of HGB: 
Direct  reading from report.
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e)Determination of TLC:
Multiply the WBC with lymphocyte % obtained from reading.
3.3. Protocol for CD4 count
a)sample :      
Peripheral  blood of  HIV patients .collect  into EDTA coated 
tubes (367856,Becton and Dickinson).Mix thoroughly with the anti 
coagulant by gently inverting the tube .about 8-10 mts    
b) Cell staining :
Add 20µl of antibody (stand)to 50µl of blood sample gently 
mix it by vortexer
Incubate the sample in the dark for 15mts
c)Fixation and rbc analysis:   
450µl of IX lysis buffer to each sample.vortex it  and incubate 
for 15mts.
Add 25 µl of fluorescent beads to each sample.
d)Calibration of the flow cytometer
e)Detection: - FACS method
f)Determination of CD4    =       Gated cell count       ×         Bead 
count per test
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                                                    Gated bead count                  Test  
volume
3.4. Limitation and precaution of study
Handling of HIV patients blood is risk for unskilled persons 
those who are not practiced with laboratory equipments 
Modes of exposure to HIV in the laboratory
LAB PROCEDURE METHODS OF TRANSMISSION
Collection of blood
Transfer of specimen
cleaning/washing
Needle  stick  injury  ,Broken 
specimen  container,  Blood 
contamination  of  hand  with  skin 
lesions or breach
Contaminated  exterior  of  the 
container
Punctural  contamination  of  skin 
from,
contaminated glass ware
sharps
contaminated work surface
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Transport  of  specimen to 
distant laboratory
Broken or leaking container
Similiarly  all  instruments  and  other  equipments  that  have 
come  into  contact  with  blood  are  assumed  to  be  potentially 
contaminated with blood borne pathogens and must be properly 
handled,cleaned or safely disposed off.
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METHODOLOGY
3.5. Data collection
Collection of data from out sources
Data  of  demographic,  general,  clinical  characteristics  and 
laboratory profile of  HIV positive patients in all  stages,  collected 
and  reviewed  from net  sources  to  find  out  the  changes  of  the 
marker  trend in  all  stages of  HIV and analyzed  their  symptoms 
persist in different stages of disease.
Collection of Existing data      
Comparison  of  results  obtained  from analysis  of  net  sources 
with experimental work or existing work is essential for conclude 
the research work. Due to limitation and precaution of handling of 
HIV  patient’s  blood,  existing  work  collected  for  further  analysis. 
Data of 50 HIV +ve patients include general characteristics, clinical 
profile  and  lab  parameters  collected  from  their  records  in  all 
departments  in  500  bedded  multi  speciality  private  tertiary  care 
teaching hospital.
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3.6. Data analysis
B. Data analysis
• The data  mainly  laboratory  profile,  symptoms  of  HIV,  and 
other  co  morbidities,  and  immunopathology  from  different 
sources  compared  and  derived  the  trend  for  CD4,  VL 
changes  in  acute  phase,  chronic  phase  and  AIDS phase. 
Also  derived  the  trend  for  HGB  and  TLC  decline  in  HIV 
progression.
• Subgrouped the 3 stages of  AIDS into further based upon 
changes in marker trend, and symptom. Classified the HIV 
progression  into  a  new  model  which  represents  the 
integrated form of changes in marker trend, symptoms, CDC 
classification and WHO classification system.
• Correlation  between  the  all  surrogate  markers  which  are 
recognized as predictors of HIV progression is studied and 
compared their significance in prediction of HIV in resource 
poor settings.
• Trend for changes of markers level (CD4 count, VL, HGB and 
TLC) in HIV infection were derived by regression analysis.
• Analysed the characteristics (Age, group, sex, co morbidity 
prevalence), clinical profile (frequently observed symptoms) 
and laboratory profile (HGB, TLC, CD4) of study population 
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from existing data and classified them into different category 
based upon their symptoms.
C. Prediction
• Predicted the CD4 for study population by,
Correlation of TLC with CD4 count and HGB level with CD4 
count, and found out the significance of combination of these 
2 models 
• Compared  the  predicted  CD4  with  actual  CD4  of  study 
population
     and find out the significance and outcomes of symptom 
based  
     Prediction,  HGB  based  prediction,  and  TLC  based 
prediction.                                
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RESULTS
4.1 Literature data analysis
A. Natural History of HIV progression
FIG:7
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Natural History of HIV infection
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B. Categories in Natural History of HIV Progression
   MONTHS 
            
CATEGORY
CDC
WHO
2 30 36 60 108 14472
     I                II               III             IV        V                 VI             VII
                       I                                               II                                 III
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CD4
VL
HGB
M/F
TLC
                        I                                         II                     III             IV
0                  5.6         3.3          3.77         3.95            4                 4.84        
6.8     
17/14                      15/12      14/11         12/10        10/9            9/8             
7/6     
1200            550         650        510           430             380            200          101 
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BMI
CD4%
S neo
β2M 
2200                       1800         1600        1500        1400           1200          
800
22                           21                                              19.5             18             
16
30                                                                                                 14            10
6.25         11.6                        13.9                           16                20             
0.2
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IL-2R
TNFα
ALBUMIN 
C-Rn
0.6                                                                                              3.5
100          350                                          900                             1200    
1.65        2.87                         4
42                                          40                               37                 35
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HGT
C. Changes in Markers trend in Entire progression of HIV
1. Trend of VL level in HIV progression
FIG:8
Viremia level in Natural progression of HIV
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3. Trend of changes in CD4 count in HIV Progression
FIG:9
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CD4 decline in progression of HIV
650
625
590
575
550
510
490
430
380
320
270
200
150
100
80
50
25
10
y = -4.446x + 661.38
R2 = 0.985
-50
50
150
250
350
450
550
650
3 9 15 21 27 33 39 45 51 57 63 69 75 81 87 93 99 105 111 117 123 129 135 141 147
Progression in months
C
D
4 
ce
ll
s\
m
m
3
3. Correlation of CD4 and VL in HIV infection
FIG:10.
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4.  HGB decline in HIV progression in MALE
Fig:11
Natural History of HGB decline in male
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5. HGB decline in HIV progression in FEMALE
FIG:12
Natural History of HGB decline in female
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D. Changes of markers trend in different categories
1. Category I&II
 CD4 decline in category I&II
FIG:13
CD4 changes in Acute phase HIV progression
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FIG:14.
VL level in HIV progression at acute phase
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  Data for Category I&II
Table :8
Progression  in 
weeks
CD4 
cells\mm3
VL  in 
logcopies\ml
HGB g\dl M/F
0 1200 0 17/14
1 1050 2.6
2 950 3.3
3 900 4
4 700 5.3
6 500 5.7
8 550 5.6
9 600 3.3
12 650 3.3 15/12
I. Change in CD4 count at 0-2 months
FIG:15.
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I. Change in VL level at 0-2 months
FIG:16.
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II. Change in CD4 count at 2-3 months
FIG: 17.
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CD4 changes in 8-12 weeks of acute infection
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II. Change in VL level at 2-3 months
FIG:18.
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VL changes in 8-12 weeks of acutue infection
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2. Category III-VI
Data for category III-VI
TABLE:9
Progression 
in months
CD4 cells\mm3 VL  log 
copies\ml
HGB g\dl
3 650 3.3 15\12
4 625 3.44 14\11
6 590 3.47
12 575 3.60
24 550 3.69
36 510 3.77 12\10
48 490 3.90
60 430 3.95
72 380 4 10\9
72
CD4 decline in category III-VI
FIG: 19.
CD4 Decline in Cat.B.Natural progression
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VL changes in Category III-V
FIG :20.
VL in Cat B Natural progression
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3. Category VI-VII
Data for Category VI-VII
TABLE: 10.
Progression 
in months
CD4 cells\mm3 VL  log 
copies\ml
HGB g\dl
72 380 4 10\9
84 320 4.7
96 270 4.74
108 200 4.84 9\8
114 150 4.95
120 100 5.4 7\6
126 80 6.3
132 50 6.6
138 25 6.7
144 10 6.8
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CD4 decline in Category VI-VII
FIG :21
CD decline in Cat.C Natural progression
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VL changes in VI-VII
FIG : 22.
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TABLE:11.  F.  Classification of  HIV infection based on symptoms 
and changes in markers trend
Categ
ory
Month
s
Symptoms(HIV,  OI, 
Drugs)
CD4 
cells\
mm3
VL 
log 
copies\
ml
HGB 
g\dl
F\M
I 2 • Fever
• Mouth ulcer
• Malaise
• Arthralgia
• Head ache
• Loss of appetite
• Rash
• Pharyngitis
• Anal ulcer
• Genital ulcer
• Weight loss
550 5.6 14\1
7
76
• Diarrhoea
• Thrush
• Voimiting
• Swollen  lymph 
glands
      Drugs
• GI distrubance
II 3 • Aseptic meningitis
• Peripheral 
neuropathy
• Facial palsy
• Guillian  Barre 
synndrome
• Branchial neuritis
• Cognitive 
impairment
650 3.38
III 36 • Mild fatigue
• Low grade fever
510 3.77 11\1
4
77
• Night sweats
IV 60 • Cervical  dysplasia 
patches
• Persistant  lymph 
adenopathy
• Sore throat
• Joint pain
• Muscle pain
• Cervical  epithelial 
neoplasia
                OI
• Severe diarrhea
• Severe Weight loss
o Drugs
• GI intolerance
• Colitis symptoms
430 3.95 10\1
2
78
V 72 • Recuurent 
respiratory  tract 
infection
         OI
• Purplish skin
• Severe  cough  and 
weight loss
• Sputum  contain 
blood
• Drugs
• Skin eruption
• Optic neuritis
• Hematological 
symptoms
• Anemia
• Lymphophenia
• Leucopenia
• Bone  marrow 
depression
380 4 9\10
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• Cardic complaints
• Tingling, numbness
Noticeable  changes  in 
the way of walk
VI 108 • Dysplasia patches
• Erythymatous 
Maculopapoular 
with  lesions 
includind palms and 
soles
  OI
• Fluffy white patch
• Red inflamed skin
• Severe irritation
• Leisons on genitals
• Patches on armbits
• Bleeding  from 
mucous membrane
• Shingles  (painful 
blister in a band of 
200 4.84 8\9
80
red skin)
• Thrush  (thick  white 
coating)
• Tingling,numbness
• Neurological 
dysfunction
• Pure RBC aplasia
• Neutropenia
• Anemia
• Thrombocytopenia
• More  than  I  month 
chronic ulcer
• Bronchitis
• Fungal  nail 
infection
• Dermatitis
Drugs
• GI intolerance
81
VII 144 • HIV
• Primary  CNS 
syndrome
• Severe  watery 
diarrhea
• Severe Weight loss 
• Gastro enteritis
        OI
• Pseudo 
membraneous 
plaques
• Pain on swallowing
• 2-3  weeks  head 
ache
• Phtophobia
• Neurological 
dysfunction
• Pure RBC aplasia
10 6.7 6\7
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• Anemia
• 2-3 week dry cough
• fever  more  than  1 
months
• Disproportionate 
breathlessness
• Sore throat
• Sneezing
• Oesophagal 
symptoms
• Reduced 
visualactivity 
hemorrohogic 
exudates  along 
retinal vessels
• Loss  of  memory 
and depression
• Paralysis
• Leisons  in 
cerebraum
83
• Unconsiousness
• More than 1 month 
chronic GI problem
• Chronic blood loss
• Anemia
• DRUGS
• Liver  function 
impaired
• Hypo kalemia
• Bone  marrow 
depression
• Weight loss
• GI intolerance
• Lactic acidosis
• Abdominal pain
• Glycosuria
• Proteinmia
• Leucopenia
• Blister formation
84
• Skin rash
• Allergy
• Skin eruption
• Anorexia
• Thrombocytopenia
• Anemia(drug d)
• Hyperglycemia
• Hyper lipidemia
• Poly urea
• Poly pagia
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4.2. Existing Data Analysis
Clinical and laboratory profile of study group
Cas
e 
No
Clas
s
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
2
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s
9 I      
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4
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A. Characteristics of subjects (N=50)
1. Age group in study population    
FIG:23. 
20-30
24%
30-40
38%
40-50
28%
>50
10%
   2. Percentage of male and female participants         
FIG: 24.                
   
Male
90%
Female
10%
    3. Comorbidity in study population 
FIG:25.
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comorbidity
Anemia
47%
OI
27%
TB
7%
Cancer
1%
others
18%
B. I. Clinical symptoms frequently observed in total study population 
1. Abdominal pain*                                
2. Acute pancreatitis                             
3. Anemia*                                             
4. Cough with expectoration                
5. Diabetes melitis                                
6. Difficulty in breathing                     
7. Enlarge lymph node*                         
8. Fever*                                                
9. Gastritis*                                            
10. Guiddiness*                                        
11. Head ache*                                         
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12. Joint pain*                                          
13. Loss of appetite*                                 
14. Loss of weight *                                
15. Multiple Liver abscess                    
16. Night sweating*                                
17. OI symptoms                                  
18. Oral candidiasis                             
19. Oral ulcer*                                         
20. Others                                              
21. Respiratory tract infection *             
22. Slurring of speech*                           
23. TB                                                    
24. Vomiting *                                         
25. Watery diarrhoea*
26. White mucoid sputum
Note : * indicates the HIV symptoms observed in study group
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Others
1. Acute Coronary syndrome
2. Bronchitis
3. Chest pain
4. Chronic ulcer
5. Decrease in urine output
6. Edema
7. Focal fitness
8. General weakness
9. Hemorrhoids
10. Ischemic Heart Disease
11. Numbness
12. Pain on swallowing
13. Pleural effusion
14. Sneezing
15. Spasm
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Symptoms observed in study group
FIG:26.
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Fig 27 Symptoms distribution
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Symptoms Distribution
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Hiv
Table 12 frequently distributed symptoms 
Sym 
ID I III IV V VI VII Sym
8 5 3 3 7 7 10 35
20 2 2 5 6 7 5 27
4 1 1 2 6 4 6 20
13 0 1 2 6 4 5 18
14 0 1 2 5 4 6 18
6 2 0 4 4 3 3 16
17 2 1 2 2 4 4 15
1 1 3 1 4 1 4 14
12 3 1 2 2 4 0 12
21 1 1 3 4 1 1 11
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25 0 0 0 3 2 4 9
10 1 0 2 1 3 1 8
9 1 0 0 3 0 3 7
3 1 0 0 0 2 4 7
22 1 0 3 0 1 1 6
7 1 0 1 2 2 0 6
24 0 2 0 2 0 2 6
5 2 0 0 1 1 1 5
26 0 1 1 1 0 2 5
23 0 0 1 1 2 1 5
11 2 0 0 0 2 0 4
16 1 1 0 0 2 0 4
18 0 1 1 1 0 1 4
19 0 1 1 0 1 1 4
15 0 0 1 0 1 0 2
2 0 0 0 0 1 1 2
Fig 28
98
Symptom ID Vs Frequency
<Hiv>
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B. II.HIV symptoms in different study group 
TABLE: 13 
Category Total  symptoms 
Frequently observed
HIV symptoms
I 15 11
II 0 0
III 7 3
IV 14 12
V 20 11
VI 16 10
VII 21 12
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Table 14
Unique symptom of HIV in entire population
Hiv VII VI V IV III I
8 8 8 8 20 8 8
20 4 20 20 6 1 12
4 14 4 4 8 20 20
14 20 14 13 21 24 17
13 13 13 14 22 21 6
6 17 17 6 4 4 5
17 1 12 1 13 13 11
1 25 6 21 14 14
12 3 10 25 17 17
21 6 25 9 12 12
25 9 3 17 10 26
10 23 12 18
3 7 7 19
9 11 24 16
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C. Laboratory parameter analysis
Mid month
Mid CD4
Mid TLC
Mid HGB
        1                2.5       18.5           38             66                90                126   
  
0               2             3             36              60             72             108           
144
       875            600      580           470            405             290           105
      2200          1800     1700         1650          1300           1100        1000   
     17/14       15/12    14.5/11.5     13/10.5      11/9.5        9.5/8.5       8/7
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TLC Median (from study)
HGB Median (from study)
CD4 Median (from study)
     2000                        1691          1536          1452           1250          850
     10.6                         11.8            11            14.2               9             8.7
                                      380                            375              197            98
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D. Predicted category of Study group
I. Population of HIV in different Category
TABLE:15
Category Study no
I 7
II 0
III 4
IV 7
V 11
VI 11
VII 10
FIG:30
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Anemia condition in Study group
TABLE : 16
Category Study no
I 2
II 0
III 2
IV 4
V 6
VI 7
VII 10
105
FIG:31.
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TLC count in Study group
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Fig 34
Age group in study population
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TABLE: 17.II. Predicted category of CD4 count measured patients
Category Study no
I 0
II 0
III 1
IV 0
108
V 4
VI 2
VII 7
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D. Prediction of CD4
TLC,HGB,AGE of  14 CD4 category
Table 18
Case 
No Class age sex HB TLC
CD4 
cells
33 V 28 m 11.4 1450 440
35 V 32 m 10.1 1456 310
109
49 III 38 m 9.6 1700 380
24 V 29 f 9.4 1482 410
11 VII 25 m 9.3 793 102
27 V 48 f 9.0 1400 324
29 VII 36 m 8.4 935 225
13 VII 32 m 8.4 810 78
46 VI 31 f 8.2 1092 205
39 VII 25 m 8.2 792 178
45 VI 24 m 8.0 1090 190
21 VII 40 m 7.6 390 108
42 VII 44 m 7.6 950 84
37 VII 52 m 7.2 896 185
Observed CD4 counts in Study population
Fig 36
110
 TLC counts in CD4 count measured patients
Fig 37
111
HGB level in CD4 count measured patient
Fig 38
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Regression analysis of 3 predictors of HIV infection
Predicded values of entire  study population
Table 19
446 337 426 0.9580 1470 1.0569
283 346 336 0.9612 1215 0.9731
300 411 419 0.9830 1240 0.9823
251 322 293 0.9530 1164 0.9542
340 338 364 0.9586 1304 1.0043
202 184 166 0.9065 1087 0.9243
186 231 197 0.9222 1061 0.9138
170 230 194 0.9220 1036 0.9031
105 173 163 0.9026 934 0.8573
186 142 139 0.8922 1061 0.9138
137 23 93 0.8520 985 0.8808
275 142 123 0.8923 1202 0.9685
137 189 169 0.9080 985 0.8808
202 147 140 0.8940 1087 0.9243
552 572 996 1.0374 1637 1.1038
910 550 1480 1.0300 2199 1.2330
763 529 1200 1.0230 1969 1.1847
381 499 623 1.0130 1368 1.0253
113
259 456 426 0.9984 1176 0.9590
527 440 688 0.9930 1598 1.0934
576 421 695 0.9864 1675 1.1139
389 417 511 0.9852 1381 1.0294
657 406 734 0.9813 1803 1.1461
576 393 633 0.9770 1675 1.1139
470 387 533 0.9750 1509 1.0682
414 370 460 0.9694 1419 1.0414
454 363 478 0.9670 1483 1.0607
414 362 447 0.9666 1419 1.0414
340 357 387 0.9648 1304 1.0043
495 351 485 0.9630 1547 1.0792
332 351 375 0.9630 1291 1.0000
389 345 404 0.9610 1381 1.0294
340 344 370 0.9604 1304 1.0043
275 339 324 0.9588 1202 0.9685
674 337 568 0.9582 1828 1.1523
422 337 411 0.9580 1432 1.0453
438 324 400 0.9537 1458 1.0531
462 322 410 0.9530 1496 1.0645
560 318 455 0.9516 1649 1.1072
170 314 243 0.9505 1036 0.9031
495 311 408 0.9495 1547 1.0792
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397 298 338 0.9450 1394 1.0334
560 285 384 0.9406 1649 1.1072
251 277 252 0.9380 1164 0.9542
381 240 247 0.9255 1368 1.0253
373 227 226 0.9210 1355 1.0212
495 210 214 0.9154 1547 1.0792
381 174 150 0.9030 1368 1.0253
251 168 151 0.9010 1164 0.9542
105 58 126 0.8640 934 0.8573
Fig 39 Observed TLC Vs TLC from HGB
0
500
1000
1500
2000
2500
33 24 49 27 35 29 46 45 37 39 21 11 42 13 9 8 22 2 25 36 30 32 18 12 26 23 43 19 14 15 48 38 44 41 31 40 20 16 34 1 50 10 28 17 47 5 4 3 7 6
Obsd TLC
p TLC from Hb
 Fig 40 Observed HGB VS HGB From TLC
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DISCUSSION
Even  before  researchers  discovered  that  lymphocyte  cells 
consisted of  subsets of  Bcells and cells derived from the thymus 
(Tcells), a decrease in the total number of lymphocytes was known 
to correlate with lack of cellular immunity and predisposition to serve 
infections  in  adults  and  children.  (1)  As  early  as  1964,  it  was 
recognized  that  certain  childhood  infections  such  as  measles 
temporarily  suppress  immune  function,  as  reflected  in  the  total 
lymphocyte count (TLC). As the field of immunology advanced, new 
laboratory tests, such as mutagen and antigen activation of cells in 
culture,  were  used  to  measure  immune  function  directly.  Further 
analysis identified 2 primary categories of T cells: CD4 cells (also 
known as “helper T cells”) and CD8 cells.
Soon after  HIV was found to be the cause of  AIDS, it  was 
shown  that  the  virus  binds  to  receptors  on  CD4cells,  enters  the 
cells,  and uses them to create new virus, destroying them in the 
process.  This  results  in  the  depletion  of  CD4  cells  and 
immunodeficiency.
With the increased availability of equipment to performCD4 counts 
and the knowledge that CD4 cells were the primary target of HIV, 
the determination of CD4 count became the standard measure of 
immunodeficiency  in  adult  HIV-infected  patients  in  recourse-rich 
countries. The relative ease of CD4 cell monitoring also led to its 
advocacy in treatment guidelines for determining when to start, stop, 
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or  change  ART and for  deciding  when  to  initiate  prophylaxis  for 
opportunistic infections 41
In resource-limited countries, wide spread and routine use of 
CD4  count  and  plasma  viral  load  in  the  management  of  HIV 
infection has not been possible, traditional methods of CD4 count 
measurement,  such  as  immunophenotyping  by  flow cytometry  or 
labeling  with  monoclonal  antibodies,  require  expensive laboratory 
equipment  ad  expertise.  Even  where  such  facilities  have  been 
established at centralized labarotories, specimens typically require 
processing  with  in  48  hours  of  sample  collection,  which  can  be 
difficult  to  ensure  in  settings  with  poor  transportation  and 
communication infrastructure .42
So many research studies conclude that anemia is frequently 
experienced by HIV +ve individuals and has been shown to be a 
strong  independent  predictor  of  disease  progression  and  death. 
HGB measurements is the simplest one for finding anemia, so HGB 
levels monitor also could be useful as predictor in HIV progression.40
WHO-2002  revised  guidelines  recommends  the  TLC 
monitoring as predictor in resource limited setting, and a 2004 study 
conducted  in  US  evaluated  TLC,  HGB  results  as  predictors  of 
clinical response to ART. The study found that TLC <1.200 cells/μl ≈ 
CD4 <200 cells/μl and H&B <10.6 G/dl ≈ CD4 < 200 cells/ μl 41
TLC is Easley obtained from the routine complete blood count 
(CBC)  with  differential  by  percentage  lymphocytes  by  leukocyte 
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count. In southern India, for example, the cost of a single TLC from 
a CBC is $1 (US) where as a single CD4 count by flow cytometry is 
approximately $30 (US). In India where the average annual income 
is  <$350  and  annual  per  capita  spending  on  health  by  the 
government  is  $133,  the  cumulative  cost  of  monitoring  HAART 
becomes a significant financial challenge. When computing cost on 
an annual basis, quarterly monitoring with TLC amounts to only $4 
per year while that of CD4 count testing is $120 per year 42
Another  one  least  method  for  classified  the  HIV  patient  is 
symptoms but calculating the persisting of particular symptoms at 
HIV progression is difficult.
Purpose of this study is to access the capability and clinical 
utility of TLC change, HGB change to serve as a surrogate marker 
for CD4  count in prediction and recommends the HAART initiation 
criteria.47 
Of the 50 patients of HIV +ve , 90 % were male ,10 % were female 
and co morbidity % of study population has given in fig (26) . More 
than  40  symptoms observed  in  study  population  among then  25 
were  HIV  and  AIDS related  symptoms.  Percentage  of  frequently 
observed symptoms has given in Table (12).
Among 50 patients 31 were anemic group and 14 patients had 
CD4 count DATA shown in fig 25,31 and 32.
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Patients were sub grouped into 7 different categories based 
up on their symptoms observed and TLC and HGB Count Decline 
data  shown  in  Table  (17,18  )  and  in  fig  (26,27,28,29)  for  each 
category.
Found  the  predicted  category  of  CD4  Count  measured 
patients as shown in Table (16) fig (35). Analysed the HGB level, 
TLC level , Age group , Sex, and category as shown in table(20) .
                    
Correlated the CD4 count of patients in different category with 
TLC count and HGB count. It showed significant correlation between 
them figure shown in (41),also we can able to predict the TLC From 
HGB and vice versa.
Unique symptoms in each category observed from analysis, 
found that abdominal pain and fever are common symptoms in each 
category. Symptoms frequency also observed as per our analysis, if 
one  HIV  patient  come  into  some  symptoms  which  are  easily 
classified with our model, will  easily able to tell  that at where he 
falled in HIV age.
 Further HGB and TLC measurement helps to fix that patient 
into exact category and predict the CD4 form both HGB and TLC. 
Also  can  able  to  predict  the  TLC by  HGB and  HGB by  TLC is 
possible  by  our  model.  Even  though  TLC and HGB showed  the 
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significant correlation with CD4 count, the combination of both is a 
very good predictor. 
By our analysis, CD4 count of patient is possible without doing flow 
cytometry test but just doing TLC and HGB measurements.
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SUMMARY & CONCLUSION
HIV infection is associated with numerous co morbidities and 
opportunistic  infection.  It  affects  total  immune  system of  human. 
Deterioration  of  immunological  parameters  is  widely  used  as 
predictor as well as prognostic marker. Current recommendations of 
initiating HAART is based on CD4  count decline.  But cost of each 
test is so high in resource poor settings. So searching of alternative 
low cost predictors in HIV progression is paramount important in HIV 
infection for poor resource settings.
Symptoms also important thing in HIV patients. WHO grouped 
the symptoms into 4 categories and CDC grouped the symptoms 
into 3 categories, which includes changes of marker trend into this; it 
will come into seven categories. This integrated model helps us to 
categorize the HIV patient where they are falling in HIV age and can 
able  to  predict  the  CD4  count  for  HIV  patients  from  TLC 
measurement,  Hemoglobin  measurement  and  combined  effect  of 
these  two  measurements.  From  our  analysis  correlation  of  both 
Hemoglobin and total lymphocyte count with CD4 are significant. WE 
conclude that TLC and HGB are good predictors for HIV progression 
in  resource limited settings,  also combined effect  of  both  is  high 
compared than Individual.
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β2 M                -             Beta 2 Microglobulin
S-neo               -             Serum Neopterin
BMI                 -            Body Mass Index 
LIST OF FIGURES
Fig.No Title name Page No.
1 Viral pathogenesis 3
2 Viral pathogenesis and immune response 4
3 HIV-1 Replication cycle in human 7
4 Natural history of HIV infection 15
5 HIV population of India in millions 25
6 Causes of anemia in HIV by lymphoma 36
7 Changes of markers in HIV infection 47
8 Trend of VL level in HIV progression 52
9 Changes in CD4 count in HIV progression 53
10 Correlation of CD4 and VL in HIV infection 53
11 HGB decline in HIV progression in Male 54
12 HGB decline in HIV progression in Female 54
13 CD4 decline in category I and II 55
14  Changes in category I and II 55
15 Changes in CD4 count at 0-2 months 56
16 Change in VL level at 0-2 months 57
17 Change in CD4 count at 2-3 months 57
18 Change in VL level at 2-3 months 58
19 CD4 decline in category III-VI 59
20 CD4 decline in category III-VI 59
21 CD4 decline in category VI-VII 61
Fig.No Title name Page No.
22 VL changes in VI-VII 61
23 Age group in study population 73
24 Percentage of Male and Female participants 73
25 Comorbidity in study population 73
26 Symptoms observed in study group 76
27 Symptoms Distribution 76
28 Symptoms ID Vs Frequency 78
29 HIV symptoms in total study group 79
30 Population of HIV in different category 83
31 Anemia condition in study group 84
32 Frequency of Anemia condition in study 
group 
85
33 Frequency TLC count in study group 85
34 Frequency of Age group in study group 86
35 Predicted category of CD4 count’s 
population
87
36 Observed CD4 counts of study population 88
37 TLC counts in CD4 counts measured 
patients
89
38 HGB level in CD4 counts measured patients 99
39 Observed TLC Vs TLC from HGB 92
40 Observed HGB Vs HGB from TLC 92
41 Observed CD4 Vs predicted CD4 93

